3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
25
Neoplasm Metastasis
11
Stomach Neoplasms
6
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Salivary Gland Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Neoplasms
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Specimen Handling
12
Magnetic Resonance Spectroscopy
12
Temozolomide
11
Radiotherapy
8
Radiation
5
Surgical Procedures, Operative
3
Biopsy
3
vorasidenib
2
trametinib
2
pembrolizumab
2
dabrafenib
2
Spinal Puncture
2
Radiotherapy, Intensity-Modulated
2
Genetic Therapy
2
Craniotomy
2
Bevacizumab
2
vocimagene amiretrorepvec
1
veliparib
1
trastuzumab deruxtecan
1
tocilizumab
1
ribociclib
1
lorlatinib
1
atezolizumab
1
abexinostat
1
Vorinostat
1
Transurethral Resection of Bladder
1
Standard of Care
1
Restraint, Physical
1
Protons
1
Proton Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Astrocytoma
×
trastuzumab deruxtecan
×
90 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled